Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

Why It Matters

The findings signal that GLP‑1 therapies are becoming integral to treating prevalent comorbidities, reshaping payer coverage models and inflating overall health‑care spending.

Key Takeaways

• 51.3% of GLP‑1 patients have at least one emerging indication diagnosis.
• OSA is the top co‑occurring condition, affecting 25.5% of users.
• GLP‑1 patient pool grew 635% between 2018 and 2024.
• New FDA approvals include OSA, CKD, MASH, and heart‑failure indications.
• Payers may need price competition, not just prior‑authorizations, to limit costs.

Pulse Analysis

The GLP‑1 market has entered a new growth phase as insurers confront a wave of patients whose treatment aligns with emerging therapeutic targets. Trilliant Health’s longitudinal claims data reveal that more than 50% of current GLP‑1 users now qualify for at least one novel indication, a shift driven by expanding FDA approvals and off‑label use. This convergence of obesity, metabolic, and cardiometabolic disorders amplifies the drug class’s relevance across a broader patient base, accelerating utilization far beyond its original diabetes niche.

Regulatory momentum has been decisive. Since semaglutide’s 2021 obesity clearance, the FDA has added tirzepatide for obstructive sleep apnea, semaglutide for chronic kidney disease and metabolic‑associated steatohepatitis, and is reviewing heart‑failure applications. These approvals are underpinned by robust phase‑3 trials showing cardiovascular, renal, and hepatic benefits, positioning GLP‑1 agents as multi‑system therapies. Consequently, clinicians are increasingly prescribing them for high‑prevalence conditions such as OSA (affecting roughly 84 million U.S. adults) and CKD (≈37 million adults), creating a sizable overlap between drug exposure and comorbidity burden.

For payers, the expanding indication landscape translates into heightened cost exposure and complex formulary decisions. Traditional utilization controls—prior authorizations and step therapy—may blunt short‑term spikes but are unlikely to curb long‑term spending as more patients meet clinically defensible criteria. Industry analysts therefore advocate for accelerated price competition, including generic and biosimilar entry, to mitigate budgetary pressure. Aligning coverage policies with emerging evidence while fostering market competition will be essential to sustain access without jeopardizing fiscal stability.